KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...

There's a clear downside to the Norwegian policy that encourages allowing elderly people to live at home for as long as ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

Maria Pasqual was a flower farmer in Maili, loved by those who encountered her. The family who lives next door to her farm ...